Cargando…

Targeted therapy for localized non-small-cell lung cancer: a review

Targeted therapies have markedly improved the management of patients with advanced non-small-cell lung cancer (NSCLC), but their efficacy in localized NSCLC is less well established. The aim of this review is to analyze trials of targeted therapies in localized NSCLC. In patients with wild-type EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Paleiron, Nicolas, Bylicki, Olivier, André, Michel, Rivière, Emilie, Grassin, Frederic, Robinet, Gilles, Chouaïd, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940012/
https://www.ncbi.nlm.nih.gov/pubmed/27462164
http://dx.doi.org/10.2147/OTT.S104938
_version_ 1782442091126718464
author Paleiron, Nicolas
Bylicki, Olivier
André, Michel
Rivière, Emilie
Grassin, Frederic
Robinet, Gilles
Chouaïd, Christos
author_facet Paleiron, Nicolas
Bylicki, Olivier
André, Michel
Rivière, Emilie
Grassin, Frederic
Robinet, Gilles
Chouaïd, Christos
author_sort Paleiron, Nicolas
collection PubMed
description Targeted therapies have markedly improved the management of patients with advanced non-small-cell lung cancer (NSCLC), but their efficacy in localized NSCLC is less well established. The aim of this review is to analyze trials of targeted therapies in localized NSCLC. In patients with wild-type EGFR, tyrosine kinase inhibitors have shown no efficacy in Phase III trials. Few data are available for EGFR-mutated localized NSCLC, as routine biological profiling is not recommended. Available studies are small, often retrospectives, and/or conducted in a single-center making it difficult to draw firm conclusions. Ongoing prospective Phase III trials are comparing adjuvant tyrosine kinase inhibitor administration versus adjuvant chemotherapy. By analogy with the indication of bevacizumab in advanced NSCLC, use of antiangiogenic agents in the perioperative setting is currently restricted to nonsquamous NSCLC. Several trials of adjuvant or neoadjuvant bevacizumab are planned or ongoing, but for the moment there is no evidence of efficacy. Data on perioperative use of biomarkers in early-stage NSCLC come mainly from small, retrospective, uncontrolled studies. Assessment of customized adjuvant or neoadjuvant therapy in localized NSCLC (with or without oncogenic driver mutations) is a major challenge.
format Online
Article
Text
id pubmed-4940012
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49400122016-07-26 Targeted therapy for localized non-small-cell lung cancer: a review Paleiron, Nicolas Bylicki, Olivier André, Michel Rivière, Emilie Grassin, Frederic Robinet, Gilles Chouaïd, Christos Onco Targets Ther Review Targeted therapies have markedly improved the management of patients with advanced non-small-cell lung cancer (NSCLC), but their efficacy in localized NSCLC is less well established. The aim of this review is to analyze trials of targeted therapies in localized NSCLC. In patients with wild-type EGFR, tyrosine kinase inhibitors have shown no efficacy in Phase III trials. Few data are available for EGFR-mutated localized NSCLC, as routine biological profiling is not recommended. Available studies are small, often retrospectives, and/or conducted in a single-center making it difficult to draw firm conclusions. Ongoing prospective Phase III trials are comparing adjuvant tyrosine kinase inhibitor administration versus adjuvant chemotherapy. By analogy with the indication of bevacizumab in advanced NSCLC, use of antiangiogenic agents in the perioperative setting is currently restricted to nonsquamous NSCLC. Several trials of adjuvant or neoadjuvant bevacizumab are planned or ongoing, but for the moment there is no evidence of efficacy. Data on perioperative use of biomarkers in early-stage NSCLC come mainly from small, retrospective, uncontrolled studies. Assessment of customized adjuvant or neoadjuvant therapy in localized NSCLC (with or without oncogenic driver mutations) is a major challenge. Dove Medical Press 2016-07-05 /pmc/articles/PMC4940012/ /pubmed/27462164 http://dx.doi.org/10.2147/OTT.S104938 Text en © 2016 Paleiron et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Paleiron, Nicolas
Bylicki, Olivier
André, Michel
Rivière, Emilie
Grassin, Frederic
Robinet, Gilles
Chouaïd, Christos
Targeted therapy for localized non-small-cell lung cancer: a review
title Targeted therapy for localized non-small-cell lung cancer: a review
title_full Targeted therapy for localized non-small-cell lung cancer: a review
title_fullStr Targeted therapy for localized non-small-cell lung cancer: a review
title_full_unstemmed Targeted therapy for localized non-small-cell lung cancer: a review
title_short Targeted therapy for localized non-small-cell lung cancer: a review
title_sort targeted therapy for localized non-small-cell lung cancer: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940012/
https://www.ncbi.nlm.nih.gov/pubmed/27462164
http://dx.doi.org/10.2147/OTT.S104938
work_keys_str_mv AT paleironnicolas targetedtherapyforlocalizednonsmallcelllungcancerareview
AT bylickiolivier targetedtherapyforlocalizednonsmallcelllungcancerareview
AT andremichel targetedtherapyforlocalizednonsmallcelllungcancerareview
AT riviereemilie targetedtherapyforlocalizednonsmallcelllungcancerareview
AT grassinfrederic targetedtherapyforlocalizednonsmallcelllungcancerareview
AT robinetgilles targetedtherapyforlocalizednonsmallcelllungcancerareview
AT chouaidchristos targetedtherapyforlocalizednonsmallcelllungcancerareview